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Abstract
Objectives To assess whether using the Tree flowchart obvi-
ates unnecessary magnetic resonance imaging (MRI)-guided
biopsies in breast lesions only visible on MRI.
Methods This retrospective IRB-approved study evaluated
consecutive suspicious (BI-RADS 4) breast lesions only vis-
ible on MRI that were referred to our institution for MRI-
guided biopsy. All lesions were evaluated according to the
Tree flowchart for breast MRI by experienced readers. The
Tree flowchart is a decision rule that assigns levels of suspi-
cion to specific combinations of diagnostic criteria. Receiver
operating characteristic (ROC) curve analysis was used to
evaluate diagnostic accuracy. To assess reproducibility by
kappa statistics, a second reader rated a subset of 82 patients.
Results There were 454 patients with 469 histopathologically
verified lesions included (98 malignant, 371 benign lesions).
The area under the curve (AUC) of the Tree flowchart was
0.873 (95%CI: 0.839–0.901). The inter-reader agreement was
almost perfect (kappa: 0.944; 95% CI 0.889–0.998). ROC
analysis revealed exclusively benign lesions if the Tree node
was ≤2, potentially avoiding unnecessary biopsies in 103
cases (27.8%).
Conclusions Using the Tree flowchart in breast lesions only
visible on MRI, more than 25% of biopsies could be avoided
without missing any breast cancer.
Key Points
• The Tree flowchart may obviate >25% of unnecessary MRI-
guided breast biopsies.
• This decrease in MRI-guided biopsies does not cause any
false-negative cases.
• The Tree flowchart predicts 30.6% of malignancies with
>98% specificity.
• The Tree’s high specificity aids in decision-making after be-
nign biopsy results.
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Introduction
Breast lesions rated as suspicious for cancer according to the
American College of Radiology Breast Imaging and
Reporting Data System (ACR BI-RADS) (e.g. assigned an
ACR BI-RADS ≥ 4 category) that were detected on breast
magnetic resonance imaging (MRI) require tissue sampling
and histopathological workup [1–3]. Unless these lesions are
visible on other imaging modalities, they require dedicated
MRI-guided, vacuum-assisted breast biopsy (VABB) to pro-
vide representative tissue sampling [1, 2, 4]. As reflected by
positive predictive values of MRI-guided biopsies below 50%
in the literature [5–8], a relevant number of benign lesions
visible on MRI undergo unnecessary VABBs that can poten-
tially be avoided. MR-guided VABB is a safe and accurate
procedure in the diagnostic workup, but its application is lim-
ited by availability, relatively high costs compared to other
biopsy techniques, and the necessity to administer
gadolinium-containing contrast agent intravenously [9].
Although minimally invasive, MR-guided biopsies carry a
low risk for complications, such as infection or bleeding [9].
There is general consent that unnecessary biopsies should be
avoided [10] by ruling out malignancy based on imaging fea-
tures. Numerous efforts have been made to decrease the num-
ber of false-positive results in standard breast MRI using ad-
ditional imaging techniques, such as diffusion-weighted
imaging (DWI), MR spectroscopy (MRS) and positron emis-
sion tomography (PET), or sophisticated evaluation of dy-
namic contrast-enhanced MRI [11–17]. Although these ap-
proaches may increase specificity, there are several issues re-
garding standardization, as well as time and cost effectiveness.
It would be thus desirable if such an increase in specificity
could be achieved using standard breast MRI sequences only.
To report imaging features and indicate suspicion for ma-
lignancy, ACR BI-RADS is the most widely used standard. It
facilitates communication among physicians with its struc-
tured common language and standardized terminology for im-
age interpretation and reporting. However, it lacks precise
rules according to which to assign imaging features (i.e. lesion
morphology and functional contrast enhancement kinetics) to
diagnostic categories. Therefore, using ACR BI-RADS, the
inter-reader agreement remains moderate, diagnostic accuracy
is variable, a relevant number of unnecessary biopsies are
performed in benign lesions, the inter-reader agreement re-
mains moderate, and diagnostic accuracy is variable [18–22].
Fig. 1 Tree flowchart following the description by Marino et al. [24].
Terminal nodes are hierarchically ordered (1–11) and represent increasing
probabilities of malignancy
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To complement the ACR BI-RADS lexicon and to increase
specificity, Baltzer et al. proposed a simple classification sys-
tem (the Tree flowchart) for breast MRI to differentiate benign
and malignant lesions on breast MRI [23].The Tree flowchart
combines five diagnostic criteria (the root sign, enhancement
kinetics, lesion margins, internal enhancement pattern and ip-
silateral oedema; Fig. 1, Table 1) to assign a diagnostic score
to each lesion, indicating the likelihood of malignancy. These
five criteria were selected from a larger pool of 17 criteria,
based on their representation of possibly malignant lesion fea-
tures [25–28] and their non-redundancy [23]. Neither the ini-
tial exploratory evaluation of the Tree flowchart [23] nor the
subsequent independent validation study [24] specifically ad-
dressed a defined clinical setting where the Tree could im-
prove clinical management.
Thus, the aim of this study was to assess whether using the
Tree flowchart obviates unnecessary MRI-guided biopsies in
MRI-only breast lesions.
Table 1 The morphological and kinetic criteria included in the Tree flowchart
Root sign The 'root sign' is characterized by a root-like
tip at the lesion margin, that is surrounded 
on both sides by concave margin segments 
(red). The ´root´ sign can vary from a single
tip to multiple spiculations. The root sign is
suspicious for malignancy
Persistent
enhancement
Progressive rise in the enhancement curve 
on early and delayed phase T1-weighted
images is considered not suspicious.
Plateau
enhancement
No further rise of signal intensity occurs on 
delayed phase T1-weighted images after
early signal increase is considered
equivocal.
Washout Decline in signal intensity on delayed 
images after early signal increase is
considered suspicious.
Margins General characteristic of the margin of a 
lesion: smooth (not suspicious) or irregular
(suspicious). Note that in a generally
smoothly bordered lesion the root sign can 
be present.
Internal 
enhancement 
pattern
The general pattern of enhancement of a 
lesion is dichotomized into suspicious 
(centripetal/rim enhancement or
inhomogeneous) or not suspicious
(centrifugal or homogeneous
enhancement).
Ipsilateral 
edema
High water-like signal on T2-weighted
images not caused by ductectasia 
surrounding a lesion or diffusely distributed
in the breast harbouring a lesion is
suggestive of breast cancer. Entirely absent
or bilateral diffuse edema is rated negative.
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Materials and methods
Study design
This cross-sectional, retrospective, single-centre study was
approved by our institutional review board (IRB). The neces-
sity for informed consent was waived. There were 454 con-
secutive patients (mean age 52±13 years) with 469 breast
lesions visible only on MRI undergoing MRI-guided VABB
and/or surgical biopsy at our institution from January 2006 to
December 2013 who were included. There was a partial over-
lap of the data analysed in this study with two prior publica-
tions [11, 22]. However, study rationale and results differed
between the studies.
Imaging and MRI-guided biopsies
Based on our ethical review board-approved study protocol,
a database was populated with the results obtained during
retrospective readings of diagnostic breast MRI scans. MRI
scans were performed in accordance with the EUSOMA
(European Society of Breast Cancer Specialists) recommen-
dations [2] at different referring institutions, on 1.5- and 3-
Tesla (T) units of different vendors, using dedicated breast
coils: seven patients (0.2%) were scanned at 1.0-T, 422
patients (93%) at 1.5-T and 25 patients (5.5%) at 3.0-T.
There were 383 examinations (84.4%) acquired using
Siemens MAGNETOM scanners (Erlangen, Germany):
Avanto (261 patients, 57.5%), Symphony (50 patients,
11%), Essenza (21 patients, 4.6%), Espree (18 patients,
4%), Trio (17 patients, 37.4%), Harmony (seven patients,
1.5%), Verio (three patients, 0.7%), Aera (three patients,
0.7%), Skyra (one patient, 0.2%) and Vision (one patient,
0.2%). Seventy-one examinations (15.6%) were acquired
on Philips Scanners (Philips Medical Systems, Best,
The Netherlands): Intera (61 patients, 13.4%), Achieva
(seven patients, 1.5%) and Ingenia (four patients, 0.9%).
The following contrast agents were applied intravenously
at dosages of 0.1 mmol gadolinium/kg body weight:
Dotarem (gadoterate meglumine/Guerbet, Villepinte,
Fig. 3 Apocrine ductal
carcinoma in situ (DCIS) Grade 2
presenting as a mass lesion with
the root sign, delayed plateau
enhancement and perifocal
oedema, resulting in a
classification as Tree node 10.
Representative axial slices of the
T1-weighted, non-enhanced
sequence (a), a T2 TIRM
sequence (b), early (c) and
delayed (d) post-contrast T1-
weighted sequences are shown
Fig. 2 Example of a non-mass
lesion: ductal carcinoma in situ
(DCIS) Grade 3, presenting as a
non-mass lesion without the root
sign, with plateau enhancement
during the delayed phase and with
irregular margins. Based on the
Tree flowchart (Fig. 1), the
described characteristics resulted
in a node 5 rating where
malignancy cannot be ruled out
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France), Multihance (gadobenate dimeglumine/Bracco
Diagnostics, Princeton, NJ, USA), Gadovist (gadobutrol/
Bayer Pharmaceuticals, Berlin, Germany), Prohance
(gadoteridol/Bracco Diagnostics, Princeton, NJ, USA) and
Omniscan (gadodiamide/ GE Healthcare, Princeton, NJ,
USA). The detailed sequence parameters of the T2-
weighted and the dynamic T1-weighted sequences are
shown in ESM 1.
All lesions classified as BI-RADS 4 (suspicious) were
biopsied under MRI-guidance at our institution on a 1.5-T
system (Avanto, Siemens) using a dedicated double breast
imaging and intervention coil (InVivo, Philips).
Written informed consent for the MRI-guided VABB was
obtained from all patients in advance.
MRI-guided VABBs were performed as previously de-
scribed [22]. For lesion localization, a shortened imaging
protocol was acquired: before and after the application of
intravenous (IV) contrast agent, dynamic, contrast-en-
hanced, T1-weighted gradient echo sequences were ac-
quired and subtraction images were obtained. The T1-
weighted sequence was repeated to verify needle position-
ing during the biopsy. After VABB, the biopsy sites were
marked with MRI-compatible radiopaque clip markers. An
experienced board-certified breast pathologist (M.R.) per-
formed histopathological tissue analyses and applied the B
classification for diagnosis [29]. Histopathological results
and the MRI were compared in interdisciplinary consen-
sus. In cases of discrepancy between imaging results and
histopathology, and in lesions with uncertain malignant
potential (B3), surgical biopsy was performed, after wire
localization, by board-certified, experienced breast sur-
geons. In case of a benign finding at histopathology, the
patients were followed up with breast MRI for at least 12
months.
Data analysis
All examinations were analysed by an experienced breast im-
aging radiologist (P.A.B, >10 years of breast MRI experi-
ence), and 82 consecutive cases were read by a second reader
independently (C.S., radiology resident) to assess inter-reader
Fig. 4 Benign columnar cell
change and flat epithelial
hyperplasia were diagnosed in
this mass lesion showing plateau
enhancement and smoothmargins
without the root sign, thus
resulting in a Tree node 2. Biopsy
could have been avoided with the
Tree classification in this lesion.
Representative slices of the T2-
weighted (a) and the unenhanced
T1-weighted sequences (b) are
shown, as well as early (c) and
delayed (d) subtractions of
contrast-enhanced T1-weighted
sequences
Fig. 5 Fibroadenomatous hyperplasia presenting as a mass lesion with
persistent enhancement and smooth borders without the root sign (note
the lobulations with konvex tips that do not fulfill the criteria of the root
sign). The lesion was thus classified as node 1 and could have been
identified as benign using the Tree flowchart. Representative slices of a
non-enhanced T1-weighted sequence (a) and subtractions of the early (b)
and delayed (c) post-contrast T1-weighted sequences are shown
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agreement. Both readers were blinded to the final histopatho-
logical diagnosis and previous reading results, if available.
The readers were asked to classify all identified lesions
following the Tree flowchart. This simple classification sys-
tem is based on five morphological and kinetic criteria (root
sign, contrast enhancement kinetics, lesion margins, internal
enhancement patterns and oedema; Table 1 and Fig. 1) evalu-
ated on T2-weighted sequences and dynamic, contrast-en-
hanced, T1-weighted sequences. The Tree flowchart contains
11 assignment categories that correspond to an increasing
probability of malignancy (1 = lowest, cancer very unlikely,
to 11 = highest, cancer very likely; Fig. 1) [23, 24]. Examples
of lesions are given in Figs. 2, 3, 4 and 5. A diagnostic cate-
gory was chosen for each lesion by following the Tree flow-
chart and was noted in a spreadsheet (Fig. 1).
Statistical analyses
SPSS 23.0 (SPSS, IBM, Chicago, IL, USA) and MedCalc 15
(MedCalc software bvba, Ostend, Belgium) were used for sta-
tistical analyses. Inter-reader agreement in the assigned Tree
categories was assessed using kappa statistics. A receiver oper-
ating characteristic (ROC) analysis was performed and the area
under the ROC curve was measured to determine overall diag-
nostic performance. Sensitivity, specificity and likelihood ratios
were calculated at different cut-off values. P-values ≤0.05 were
considered statistically significant. Two cut-off values, to rule
out and rule in malignancy, were selected according to the
calculated sensitivities, specificities and numbers of false-
positive and false-negative results (low cut-off value with
highest sensitivity and lowest false-positive results; high cut-
off value with high specificity and low false-negative results).
Results
Patients and lesions
Ninety-eight of the included 469 breast lesions (20.9%) were
histopathologically diagnosed as malignant, and 371 (79.1%)
lesions as benign.
There were 270 lesions (57.6%) that presented as masses,
whereas 199 (42.4%) were non-mass lesions. Of all 270 mass
lesions, 68 (25.2%) were malignant and 202 (74.8%) benign.
Of the 199 non-mass lesions, 30 (15.1%) were malignant and
169 (84.9%) benign. Detailed size descriptions and descrip-
tive statistics of histopathological diagnoses are given in
Tables 2 and 3.
ROC curve analyses
Using the Tree flowchart for all lesions, the overall accu-
racy represented by the area under the ROC curve (AUC)
Table 2 Size distributions in mass and non-mass lesions stratified by histopathological results
Lesion type n Mean diameter (mm) Histology n Mean diameter (mm)
Mass lesions 270 9±5 (SD) Malignant 68 11±6 (SD)
Benign 202 9±5 (SD)
Non-mass lesions 199 26±15 (SD) Malignant 30 35±16 (SD)
Benign 169 24±14 (SD)
Total 469 16±13 (SD) Malignant 98 18±15 (SD)
Benign 371 16±12 (SD)
SD standard deviation, n number
Table 3 Descriptive statistics for histopathological diagnoses among
all lesions stratified by Tree nodes
Node Benign High-risk DCIS Invasive cancer Total
1 n 69 8 0 0 77
% 89.6 10.4 0.0 0.0
2 n 23 3 0 0 26
% 88.5 11.5 0.0 0.0
3 n 154 45 9 9 209
% 73.7 21.5 4.3 4.3
4 n 11 1 0 1 13
% 84.6 7.7 0.0 7.7
5 n 31 9 10 8 58
% 53.4 15.5 17.2 13.8
7 n 10 4 5 9 28
% 35.7 14.3 17.9 32.1
8 n 10 6 6 2 24
% 41.7 25.0 25.0 8.3
9 n 4 1 1 11 17
% 23.5 5.9 5.9 64.7
10 n 3 0 2 5 10
% 30.0 0.0 20.0 50.0
11 n 1 0 0 6 7
% 14.3 0.0 0.0 85.7
∑ n 316 77 31 45 469
% 67.4 16.4 6.6 9.6 100.0
n number, ductal carcinoma in situ, High-risk high-risk lesion
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was 0.873 (95% CI: 0.839–0.901; P<0.0001) (Fig. 6).
Detailed results using the Tree flowchart in all lesions,
masses or non-mass lesions, and details of different cut-
off levels and their diagnostic parameters, are shown in
Tables 4, 5 and 6. For mass lesions, the AUC for lesion
diagnosis was 0.902 (95% CI: 0.860–0.935; P<0.0001),
whereas in non-mass lesions the AUC was 0.786 (95%
CI: 0.722–0.841; P<0.0001) (Fig. 6). MRI units by two
vendors were used in this study: Siemens (n = 383) and
Philips (n = 71) (ESM 1). The diagnostic performance
using the Tree algorithm did not differ between cases ex-
amined on either vendor’s scanners (AUC Siemens =
0.880, standard error = 0.019; AUC Philips = 0.859, stan-
dard error = 0.056; P=0.724).
Of 371 benign lesions, 103 (27.8%) (99 mass and four non-
mass lesions) could have been predicted using the Tree flow-
chart, with a cut-off of ≤2 in mass and non-mass lesions ruling
out malignancy, without gaining any false-negative results
(NPV = 100%). A cut-off of ≤2 means that all lesions, but
without the root sign and with persistent or plateau enhance-
ment regardless of the lesion margins (smooth or irregular),
would be considered benign.
A cut-off of >8 in the Tree flowchart to rule in malignancy
would have predicted 30 of 98 true-positive findings (30.6%),
with a specificity of 98.9% and a positive likelihood ratio of
28.4 (Table 4). A cut-off of >8 includes all lesions showing
washout with or without the root sign and lesions with plateau
enhancement and the root sign.
Table 4 Diagnostic parameters and cut-off values of the Tree flowchart in all lesions included in the study
All lesions
Cut-off Sens 95% CI Spec 95% CI +LR −LR
≥1 100% (98/98) 96.3–100 0% (0/371) 0–1 1
>2 100% (98/98) 96.3–100 27.8% (103/371) 23.3–32.6 1.38 0
>3 81.6% (80/98) 72.5–88.7 79.3% (294/371) 74.8–83.3 3.93 0.23
>4 80.6% (79/98) 71.4–87.9 82.5% (306/371) 78.2–86.2 4.6 0.24
>5 61.2% (60/98) 50.8–70.9 93% (345/371) 89.9–95.4 8.74 0.42
>7 40.8% (40/98) 31.0–51.2 95.2% (353/371) 92.4–97.1 8.41 0.62
>8 30.6% (30/98) 21.7–40.7 99% (367/371) 97.3–99.7 28.39 0.7
>9 16.3% (16/98) 9.6–25.2 99.7% (370/371) 98.5–100 60.57 0.84
>10 7.1% (7/98) 2.9–14.2 100% (371/371) 99–100 0.93
>11 0% (0/98) 0–3.7 100% (371/371) 99–100 1
n number, Ben benign,Mal malignant, Sens sensitivity, CI confidence interval, Spec specificity, +LR positive likelihood ratio, −LR negative likelihood
ratio, ∑ sum
Fig. 6 Receiver operating characteristic (ROC) curves of all lesions included in the study, mass lesions and non-mass lesions. Details on the area under
the curve (AUC) are given in the text and on diagnostic cut-off values in Tables 4, 5 and 6
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Inter-reader agreement
Two readers independently read 82 consecutive cases. The
kappa agreement among the two readers for the characteriza-
tion of breast lesions according to the Tree flowchart was
almost perfect (k =0.944 [95% CI: 0.889–0.998]).
Discussion
Our study shows that using a simple classification system (the
Tree flowchart), malignancy can be excluded in 27.8% of
MRI-only lesions previously classified as BI-RADS 4, with-
out resulting in any false-negative findings, thus leading to a
substantial decrease in unnecessary biopsies. Therefore, the
Tree flowchart holds the potential to reduce the number of
costly and time-consuming MRI-guided biopsies, and there-
fore to decrease healthcare costs, patient discomfort and the
risk of possible adverse effects due to the invasive procedure.
The Tree flowchart is intuitive and suitable for readers of
different levels of experience, and it is easily applicable in
the routine clinical setting, as it requires standard breast MRI
sequences only.
As the Tree flowchart is based on T2-weighted se-
quences and dynamic, contrast-enhanced, T1-weighted se-
quences that are generally recommended for every breast
MRI, it does not require any additional imaging [2]. Of
note, short tau inversion recovery (STIR) sequences are as
suitable as T2-weighted TSE sequences for the assess-
ment of oedema [28]. Furthermore, the Tree flowchart is
based on simple dynamic and morphological features.
Thus, its application does not require any extra reading
Table 5 Diagnostic parameters and cut-off values of the Tree flowchart in mass lesions
Mass lesions
Cut-off Sens 95% CI Spec 95% CI +LR −LR
≥1 100% (68/68) 94. 7–100 0% (0/202) 0–1.8 1
>2 100% (68/68) 94.7–100 49% (99/202) 41.9–56.1 1.96 0
>3 88.2% (60/68) 78.1–94.8 72.3% (146/202) 65.6–78.3 3.18 0.16
>4 86.8% (59/68) 76.4–93.8 78.2% (158/202) 71.9–83.7 3.98 0.17
>5 75% (51/68) 63–84.7 89.1% (180/202) 84–93 6.89 0.28
>7 50% (34/68) 37.6–62.4 92.6% (187/202) 88–95.8 6.73 0.54
>8 42.7% (29/68) 30.7–55.2 98% (198/202) 95–99.5 21.54 0.59
>9 23.5% (16/68 14.1–35.4 99.5% (201/202) 97.3–100 47.53 0.77
>10 10.3% (7/68) 4.2–20.1 100% (202/202) 98.2–100 0.9
>11 0% (0/68) 0–5.3 100% (202/202) 98.2–100 1
n number, Ben benign,Mal malignant, Sens sensitivity, CI confidence interval, Spec specificity, +LR positive likelihood ratio, −LR negative likelihood
ratio, ∑ sum
Table 6 Diagnostic parameters and cut-off values of the Tree flowchart in non-mass lesions.
Non-mass lesions
Cut-off Sens 95% CI Spec 95% CI +LR -LR
≥1 100% (30/30) 88.4–100 0% 0–2.2 1
>2 100% (30/30) 88.4–100 2.37% (4/169) 0.6–5.9 1.02 0
>3 66.67% (20/30) 47.2–82.7 87.57% (148/169) 81.6–92.1 5.37 0.38
>5 30% (9/30) 14.7–49.4 97.63% (165/169) 94.1–99.4 12.67 0.72
>7 20% (6/30) 7.7–38.6 98.22% (166/169) 94.9–99.6 11.27 0.81
>8 3.33% (1/30) 0.1–17.2 100% (169/169) 97.8–100 0.97
>9 0% (0/30) 0–11.6 100% (169/169) 97.8–100 1
n number, Ben benign,Mal malignant, Sens sensitivity, CI confidence interval, Spec specificity, +LR positive likelihood ratio, −LR negative likelihood
ratio, ∑ sum
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or computational time, as the additional acquisition of
DWI would, for example [30, 31].
To date, lesion analysis based on the Tree flowchart does
not include additional functional imaging, such as DWI or
MR spectroscopy. Several studies have shown that DWI, as
an adjunct to conventional breast MRI, holds the potential to
reduce false-positive results and increase specificity with low-
er ADC values exhibited by malignant versus benign lesions
[32–35]. In an analogous fashion, DWI may be combined
with the Tree flowchart. Considering the current trend of com-
bining information from multiple sources, referred to as Big
Data, it is conceivable that more complex computer-assisted
algorithms will be developed that rely not only on semantic
and agnostic imaging features, but also on clinical background
information as well as follow-up examinations. However,
there are limitations concerning artifacts and spatial distor-
tions, and different DWI approaches have prevented the de-
termination of a generalizable ADC threshold value to distin-
guish malignant from benign lesions [34, 36–38].
The signs included in the Tree flowchart (root sign, enhance-
ment kinetics, lesion margin, internal enhancement pattern and
ipsilateral oedema) were selected initially based on their non-
redundancy and the association with malignant breast lesions
[23, 25–27]. More recent studies have proven the reliability
and significance of these signs [17, 24, 39–41]. The Tree flow-
chart was initially evaluated in an exploratory study [23], and
thereafter validated in a single clinical centre [24]. In this study,
the Tree flowchart was applied to all patients undergoing MRI-
guided VABBs in a large tertiary breast-care centre, where pa-
tients present with imaging acquired either at the same centre or
at other institutions for a second reading of their MRI. This
setting allows the application of the Tree flowchart to images
from different clinical centres. After the initial two studies on
homogeneous patient cohorts, this study set out to test the prac-
tical application of this decision algorithm. In the daily practice of
an assessment centre, breast radiologists need to deal with imag-
ing of varying quality. This is a setting where the Tree flowchart
can show its true potential to reduce unnecessary breast biopsies.
This study aimed to establish the diagnostic value of the Tree
flowchart in suspicious lesions visible only on MRI in order to
provide clinical guidance in this setting. Rather than the mere
application of a single cut-off value at the left upper part of the
ROC curve, which maximizes the sum of sensitivity and spec-
ificity, different cut-off values can be applied according to the
population in question to rule-out or rule-in malignancy [42].
Marino et al. recommended a cut-off value of ≤4 to rule-out
malignancy in their cohort [24]. We identified a non-negligible
number ofmalignant lesions in Tree scores 3 and 4 in our cohort
of MRI-only lesions (false negative score 3 lesions comprised 9
DCIS, 8 IDC and one ILC and the only false negative score 4
lesion measured 4 mm on the MRI images and histopathology
revealed a 1.5 mm invasive mucinous carcinoma). Although
the number of invasive cancers in this group was very small
at 4.5% (ten of 222), a cut-off of ≤2 might be preferable in the
investigated setting to achieve the highest possible
sensitivity. In this respect, score 4 deserves further research as
we only identified one malignant lesion in this small subgroup.
Both the MRI BI-RADS terminology and the Tree flow-
chart show higher diagnostic accuracy in mass lesions than in
non-mass lesions [43–46]. In MRI-only mass lesions, the Tree
flowchart improved diagnostic accuracy by correctly identify-
ing 99 benign lesions out of 270 lesions previously classified
as BI-RADS 4 (33.3%) and four benign lesions out of 199
non-mass lesions (2.0%).
This study shows that the Tree flowchart can guide
decision-making after discrepant results between MRI-guided
biopsy and imaging. A relevant rate of false-negative histo-
pathological results are initially obtained byMRI-guided biop-
sy of suspicious breast lesions visible on MRI (0–17%) [6, 22,
47–49]. In these cases, potential radiological-pathological mis-
match needs to be assessed.With a test that would provide high
specificity, such as the Tree flowchart, the radiologist may
confidently request surgical biopsy after a negative histopath-
ological result [9, 22]. This is particularly the case for lesions
assigned a Tree result of >8, resulting in a positive likelihood
ratio of >28, and thus practically ruling in malignancy. A neg-
ative biopsy result in such a case should immediately be re-
ferred either to repeat-biopsy or open surgery.
Two radiologists with different experience in breast MRI
evaluated lesions according to the Tree flowchart with almost
perfect inter-reader agreement, demonstrating that the Tree
flowchart is easily applicable.
The primary limitation of this study was that the standard
MRI scans analysed in this study were acquired on different
scanner types at different field strengths and with different se-
quence parameters. On the one hand, the different image qual-
ities and imaging protocols may have limited imaging interpre-
tation based on the Tree flowchart and may be one reason why
the rate of malignancies in flowchart nodes 3 and 4 was found to
be somewhat higher than that previously reported [24]. On the
other hand, the inclusion of MRI scans of different image qual-
ities shows the reliability of the Tree flowchart in a realistic and
heterogeneous setting of MR images, as may be seen at any
reference centre offeringMRI-guided VABB to patients referred
from other institutions. The high inter-reader agreement and the
diagnostic accuracy reported in this setting for both mass and
non-mass lesions prove the applicability of the Tree flowchart in
this heterogeneous cohort. In addition, subgroup analysis did not
show a significant influence of MRI vendor on the accuracy of
the Tree flowchart, thus corroborating its robustness regarding
imaging protocol variations. Furthermore, only histopathologi-
cally verified MRI-only lesions were included in this study.
Thus, the results may not apply to a general population or to
all lesions visible on MRI in a similar manner. Further studies
will be necessary to evaluate the applicability of the Tree flow-
chart to different subpopulations.
Eur Radiol (2017) 27:3799–3809 3807
In conclusion, this study showed that the Tree flowchart,
with a cut-off value of ≤2, can reduce the number of biopsies
in MRI-only lesions by as much as 27.8%, with no false-
negative cases, thus potentially decreasing healthcare costs
and patient discomfort.
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